Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Assets over the past 12 years, most recently at $899.4 million for Q4 2025.

  • Quarterly results put Assets at $899.4 million for Q4 2025, up 21.15% from a year ago — trailing twelve months through Dec 2025 was $899.4 million (up 21.15% YoY), and the annual figure for FY2025 was $899.4 million, up 21.15%.
  • Assets for Q4 2025 was $899.4 million at Viridian Therapeutics, Inc.\DE, up from $577.1 million in the prior quarter.
  • Over the last five years, Assets for VRDN hit a ceiling of $899.4 million in Q4 2025 and a floor of $118.2 million in Q2 2021.
  • Median Assets over the past 5 years was $437.8 million (2022), compared with a mean of $445.1 million.
  • Biggest five-year swings in Assets: soared 573.73% in 2021 and later decreased 25.38% in 2023.
  • Viridian Therapeutics, Inc.\DE's Assets stood at $203.7 million in 2021, then surged by 113.58% to $435.1 million in 2022, then grew by 12.72% to $490.4 million in 2023, then skyrocketed by 51.38% to $742.4 million in 2024, then grew by 21.15% to $899.4 million in 2025.
  • The last three reported values for Assets were $899.4 million (Q4 2025), $577.1 million (Q3 2025), and $582.3 million (Q2 2025) per Business Quant data.